author-photo

Todd M. Zimmerman

University of Chicago

129

Papers

4486

Citations

Citation Trend

Filter By

Papers (86) Sort By

Journal Conference Others

Real-World Testing Patterns for Risk Assessment and Implications on the Adoption of Novel Therapeutics in Chronic Lymphocytic Leukemia: IGHV Mutation Status, FISH Cytogenetic, and Immunophenotyping

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.

2021 The Lancet Haematology
Show All
- Source
- Cite
- Save
Citations (1)
Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenström macroglobulinemia (WM): Matching-adjusted indirect comparisons.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (3)
Pilot Study of Regulatory T-Cell Depletion in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma

2019 Biology of Blood and Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (0)
Expression of functional folate receptors in multiple myeloma

2018 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (10)
A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (NPI‐0052‐107): final study results

2018 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (38)
5-Hydroxymethylcytosine of Circulating Cell-Free DNA in Plasma: A Novel Non-Invasive Marker for Progression and Prognosis in Multiple Myeloma

2017 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Biology and management of unusual plasma cell dyscrasias

2017
- Todd M. Zimmerman
- Shaji Kumar
Show All
- Source
- Cite
- Save
Citations (1)
Weekly MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed/refractory multiple myeloma (MM): Results from a phase I study after full enrollment.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (15)